Perspective Therapeutics (CATX) said Friday its updated interim findings from phase 1/2a study of radiopharmaceutical therapy for advanced neuroendocrine tumors have shown continued patient safety and early signs of efficacy, supporting further dose-finding research.

Nine patients with unresectable or metastatic somatostatin receptor type 2-expressing tumors completed treatment as of Jan. 10, the company said.

Perspective Therapeutics said no dose-limiting toxicities or severe adverse events emerged, and there was no reported decline in renal function, adding that hematologic side effects, such as reduced lymphocyte counts and mild anemia, were limited to grades 1 and 2.

The trial is ongoing at multiple sites for patients who have not previously received radiopharmaceutical therapy and whose disease progressed in the past year, it added.

Shares of the company were up about 4.1% in recent trading.

Price: 3.78, Change: +0.15, Percent Change: +4.13